Pharmacotherapy to control behavioral symptoms in children with autism
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Autistic disorder, Asperger's disorder, and pervasive developmental disorder not otherwise specified (PDD-NOS) are pervasive developmental disorders (PDDs) frequently associated with behavioral symptoms that may require pharmacotherapy to manage. AREAS COVERED: Behavioral symptoms in children with autism include interfering repetitive behaviors, irritability, and hyperactivity and inattention, among others. The psychotropic medications examined in this review include: serotonin reuptake inhibitors, typical and atypical antipsychotics, medications used to treat attention-deficit/hyperactivity disorder, naltrexone, buspirone, divalproex sodium, lamotrigine, levetiracetam, memantine, mirtazapine, riluzole, pioglitazone, and topiramate. EXPERT OPINION: For the treatment of interfering repetitive behaviors, serotonin reuptake inhibitors demonstrate less efficacy and are more poorly tolerated in children with autism compared to adults. Antipsychotics are the most efficacious drugs for the treatment of irritability in children with autism and other PDDs. For the treatment of hyperactivity and inattention, psychostimulants demonstrate some benefit. However, they are overall less efficacious and cause more side effects in children with PDDs compared to typically developing children with attention-deficit/hyperactivity disorder. Results from double-blind, placebo-controlled trials of these agents and others for the treatment of the behavioral symptom domains described above will be discussed in this review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574 · cited 1×
“One study of risperidone in children with autism, aged 5 -- 17 years, revealed a 57% decrease in irritability as measured by the ABC-I subscale, compared with 14% in the placebo group [47].”
MethodSelf-citationAripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder
Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., Carson, W. H., & Findling, R. L. (2009) · Pediatrics · doi:10.1542/peds.2008-3782 · Cited by 613 · cited 1×
“6 Aripiprazole Following two large, double-blind, placebo-controlled studies, aripiprazole became FDA approved for the treatment of irritability in children and adolescents with autistic disorder, aged 6 -- 17 years [68,69].”
BackgroundLecavalier, L. (2006) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0147-5 · Cited by 569 · cited 1×
“Moderate-to-severe irritability occurs in up to 30% of children and adolescents with PDDs [4].”
Background(2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1266 · Cited by 521
King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., Donnelly, C. L., Anagnostou, E., Dukes, K., Sullivan, L., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.30 · Cited by 482
Goldstein, S., & Schwebach, A. J. (2004) · Journal of Autism and Developmental Disorders · doi:10.1023/b:jadd.0000029554.46570.68 · Cited by 412 · cited 1×
“Although a diagnosis of a PDD is excluded with a concurrent diagnosis of ADHD, an estimated 40 -- 59% of children diagnosed with PDDs also meet criteria for ADHD [5,6].”
BackgroundClonidine Treatment of Hyperactive and Impulsive Children with Autistic Disorder
JASELSKIS, C. A., COOK, E. H., FLETCHER, K. E., & LEVENTHAL, B. L. (1992) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199210000-00005 · Cited by 328
Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial
ARNOLD, L. E., AMAN, M. G., COOK, A. M., WITWER, A. N., HALL, K. L., THOMPSON, S., & RAMADAN, Y. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000231976.28719.2a · Cited by 260
Risperidone in Children With Autism: Randomized, Placebo-Controlled, Double-Blind Study
Nagaraj, R., Singhi, P., & Malhi, P. (2006) · Journal of Child Neurology · doi:10.1177/08830738060210060801 · Cited by 214
Naltrexone in autistic children: Behavioral symptoms and attentional learning
CAMPBELL, M., ANDERSON, L. T., SMALL, A. M., ADAMS, P., GONZALEZ, N. M., & ERNST, M. (1993) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199311000-00024 · Cited by 210 · cited 1×
“The effective treatment of core social impairment has not been observed [95-99].”
BackgroundMulder, E. J., Anderson, G. M., Kema, I. P., de Bildt, A., van Lang, N. D., den Boer, J. A., & Minderaa, R. B. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200404000-00016 · Cited by 199
Use of clonidine in children with autism spectrum disorders
Ming, X., Gordon, E., Kang, N., & Wagner, G. C. (2008) · Brain and Development · doi:10.1016/j.braindev.2007.12.007 · Cited by 183 · cited 1×
“There is one open-label study that found clonidine helpful for sleep initiation and maintenance in children with PDDs, specifically reducing sleep initiation latency and night awakening [90].”
BackgroundMCBRIDE, P. A., ANDERSON, G. M., HERTZIG, M. E., SNOW, M. E., THOMPSON, S. M., KHAIT, V. D., SHAPIRO, T., & COHEN, D. J. (1998) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199807000-00017 · Cited by 141 · cited 1×
“Serotonin abnormalities are implicated in the pathophysiology of PDDs [8-10], but studies examining the effectiveness of SRIs in the treatment of PDDs have yielded mixed results.”
ResultPosey, D. J., Aman, M. G., McCracken, J. T., Scahill, L., Tierney, E., Arnold, L. E., Vitiello, B., Chuang, S. Z., Davies, M., Ramadan, Y., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.028 · Cited by 131
Self-citationBrief report: A double-blind study of naltrexone in infantile autism
Leboyer, M., Bouvard, M. P., Launay, J.-M., Tabuteau, F., Waller, D., Dugas, M., Kerdelhue, B., Lensing, P., & Panksepp, J. (1992) · Journal of Autism and Developmental Disorders · doi:10.1007/bf01058158 · Cited by 130 · cited 1×
“The effective treatment of core social impairment has not been observed [95-99].”
BackgroundPosey, D. J., Puntney, J. I., Sasher, T. M., Kem, D. L., & McDougle, C. J. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/1044546041649084 · Cited by 127 · cited 1×
“Response rate in a retrospective chart review of children with PDDs receiving guanfacine IR was only 24% [92].”
BackgroundSelf-citationGuanfacine in children with autism and/or intellectual disabilities
Handen, B. L., Sahl, R., & Hardan, A. Y. (2008) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e3181739b9d · Cited by 126 · cited 1×
“The only double-blind, placebo-controlled trial used a cohort of 11 children with developmental disabilities, seven of whom had autism or PDD-NOS, treated with guanfacine IR in addition to concomitant psychotropic medications [91].”
BackgroundPosey, D. J., Wiegand, R. E., Wilkerson, J., Maynard, M., Stigler, K. A., & McDougle, C. J. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.599 · Cited by 117
Self-citationBuitelaar, J. K., van der Gaag, R. J., & van der Hoeven, J. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0203 · Cited by 113
Bouvard, M. P., Leboyer, M., Launay, J.-M., Recasens, C., Plumet, M.-H., Waller-Perotte, D., Tabuteau, F., Bondoux, D., Dugas, M., Lensing, P., et al. (1995) · Psychiatry Research · doi:10.1016/0165-1781(95)02601-r · Cited by 112 · cited 1×
“The effective treatment of core social impairment has not been observed [95-99].”
BackgroundThe Role of Psychosocial Interventions in Bipolar II Disorder: What Do We Know?
Swartz, H. A. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0508e15 · Cited by 107
Marcus, R. N., Owen, R., Manos, G., Mankoski, R., Kamen, L., McQuade, R. D., Carson, W. H., Corey-Lisle, P. K., & Aman, M. G. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0121 · Cited by 82 · cited 1×
“A long-term, open-label study considered aripiprazole safe, well tolerated, and able to reduce irritability for up to 1 year in patients with autism, aged 6 -- 17 years [70,71].”
BackgroundGreenhill, L., Beyer, D. H., Finkleson, J., Shaffer, D., Biederman, J., Conners, C. K., Gillberg, C., Huss, M., Jensen, P., Kennedy, J. L., et al. (2002) · Journal of Attention Disorders · doi:10.1177/070674370200601s11 · Cited by 80 · cited 1×
“1 Methylphenidate Psychostimulants are the pharmacologic treatments of choice in typically developing children with ADHD, with a response rate of 70 -- 80% [76,77].”
Background
Cited by
Marble Burying and Nestlet Shredding as Tests of Repetitive, Compulsive-like Behaviors in Mice
Angoa-Pérez, M., Kane, M. J., Briggs, D. I., Francescutti, D. M., & Kuhn, D. M. (2013) · Journal of Visualized Experiments · doi:10.3791/50978 · Cited by 388
Sleep in Children With Autism Spectrum Disorder
Kotagal, S., & Broomall, E. (2012) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2012.05.007 · Cited by 270
Nicosia, N., Giovenzana, M., Misztak, P., Mingardi, J., & Musazzi, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126521 · Cited by 135
Autologous Bone Marrow Mononuclear Cell Therapy for Autism: An Open Label Proof of Concept Study
Sharma, A., Gokulchandran, N., Sane, H., Nagrajan, A., Paranjape, A., Kulkarni, P., Shetty, A., Mishra, P., Kali, M., Biju, H., et al. (2013) · Stem Cells International · doi:10.1155/2013/623875 · Cited by 110
“Many treatment options have been studied for adults and children with autism such as behavioral and developmental interventions, vocational therapy, pharmacotherapy, etc [18,19].”
Coleman, D. M., Adams, J. B., Anderson, A. L., & Frye, R. E. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2018.0121 · Cited by 56
“…review of one RDBPCT and four open-label studies indicated that it significantly improved irritability, hyperactivity, stereotypy, and, to a lesser degree, anxiety and depression, but often caused decreased appetite, agitation, hyperactivity, and cognitive difficulties (Doyle and Mcdougle 2012).”
Background
Metadata
- Authors
- Doyle, C. A., & McDougle, C. J.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2012-05-03
- Volume
- 13
- Issue
- 11
- Pages
- 1615-1629
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2156712014
- Cited by
- 63
- References
- 23
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.